問卷

TPIDB > Study Site > 收納受試者人數排名

Search Result

List

82Cases

2018-03-16 - 2024-12-05

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

2018-12-30 - 2024-12-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting4Sites

Terminated2Sites

2018-04-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

2017-12-21 - 2020-04-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2016-10-10 - 2022-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting3Sites

Terminated3Sites

2016-04-01 - 2020-11-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated3Sites

2017-01-18 - 2020-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated3Sites

2017-08-10 - 2021-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated12Sites

2017-06-01 - 2024-04-08

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated9Sites

2016-12-15 - 2020-06-08

Phase III

Not yet recruiting
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Asian Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine
  • Condition/Disease

    Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Keytruda

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites